Arzneimitteltherapie in der Gastroenterologie – Stand und Perspektiven
- PMID: 34788872
- DOI: 10.1055/a-1645-0207
Arzneimitteltherapie in der Gastroenterologie – Stand und Perspektiven
Conflict of interest statement
Prof. Dr. Britta Siegmund has served as consultant for AbbVie, Arena, BMS, Boehringer Ingelheim, Celgene, Falk, Galapagos, Janssen, Lilly, Pfizer, Prometheus and Takeda and received speakerʼs fees from AbbVie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, Takeda [served as representative of the Charité]. Prof. Dr. Stefan Endres hat eine Lizenzvereinbarung mit TCR2 (Biotechfirma, Cambridge, USA).
MeSH terms
LinkOut - more resources
Full Text Sources
